Trials / Terminated
TerminatedNCT04255862
A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
An Open-Label, Single-Center, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector presentation, in healthy study participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period. |
Timeline
- Start date
- 2020-02-12
- Primary completion
- 2021-04-26
- Completion
- 2021-04-26
- First posted
- 2020-02-05
- Last updated
- 2025-04-10
- Results posted
- 2025-04-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04255862. Inclusion in this directory is not an endorsement.